Diagnostic ClarityThe company did not provide much detail into the OncoSignature diagnostic, limiting direct comparisons to other diagnostics.
Drug EfficacyPatients not enriched with OncoSignature did not respond to ACR-368, suggesting the necessity of patient selection for effective treatment.
Scientific UnderstandingWhile BOLD's focus on extra-chromosomal DNA is groundbreaking, the biological role of ecDNA is not fully understood, introducing inherent risks to their novel therapeutic approaches.